Palladino, ClaudiaGómez, María Luisa NavarroSoler-Palacín, PereGonzález-Tomé, María IsabelDe Ory, Santiago J.Espiau, MaríaHoyos, Santiago PérezLeón-Leal, Juan AntonioMéndez, MaríaMoreno-Pérez, DavidGuasch, Claudia FortunySierra, Antoni MurGuruceta, Itziar PochevilleGuillén, Santiago MorenoBriz, VerónicaCoRISpe Working Group2024-01-242024-01-242015Palladino C, Gómez MLN, Soler-Palacín P, González-Tomé MI, De Ory SJ, Espiau M, et al. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS [Internet]. 23 de outubro de 2015;29(16):2155–9. Disponível em: https://journals.lww.com/00002030-201510230-00015http://hdl.handle.net/10451/62088Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.engadolescentschildrenHAARTHIV-1maravirocjournal article2023-02-09cv-prod-118552910.1097/QAD.00000000000008192-s2.0-84964904223